Skip to main content

Table 3 Intention to treat data with no adjustments

From: The effect of marine n-3 polyunsaturated fatty acids on cardiac autonomic and hemodynamic function in patients with psoriatic arthritis: a randomised, double-blind, placebo-controlled trial

 

n-3 PUFA  (n = 68)

  

Control  (n = 60)

   
 

Baseline

Week 24

Difference (CI)

Baseline

Week 24

Difference (CI)

P

Heart rate, min−1

63.83

63.29

−0.61 (−1.92; 0.70)

63.39

64.38

0.96 (−0.55; 2.47)

0.12

RR, ms

956.55

969.94

13.38 (−5.06; 31.83)

964.02

950.53

−13.48 (−35; − 8.69)

0.06

PNN50 %

10.68

11.29

0.62 (−3.25; 4.48)

15.83

14.37

−1.46 (−4.76; 1.84)

0.42

SDNN ms

49.37

48.12

−1.24 (−8.46; 5.97)

49.71

47.41

−2.30 (−6.79; 2.20)

0.81

RMSSD ms

36.59

37.58

0.99 (−7.13; 9.12)

39.84

39.15

−0.69 (−6.23; 4.85)

0.73

Peripheral systolic BP mmHg

138.20

134.53

−3.67 (−6.69; −0.65)

134.41

133.18

−1.23 (−4.59; 2.14)

0.28

Peripheral diastolic BP mmHg

82.61

81.82

−0.79 (−2.35; 0.77)

82.36

80.92

−1.44 (−3.26; 0.39)

0.59

PWV m/s

7.80

7.81

0.01 (−0.44; 0.46)

7.40

7.48

0.08 (−0.33; 0.49)

0.82

Central systolic BP mmHg

114.82

112.24

−2.58 (−4.84; −0.32)

113.29

111.38

−1.91 (−4.77; 0.95)

0.71

Central diastolic BP

mmHg

96.04

93.76

−2.28 (−4.10; −0.47)

95.45

94.17

−1.29 (−3.51; 0.94)

0.49

PWA AIx

26.42

27.54

1.12 (−0.56; 2.80)

26.97

25.82

−1.15 (−2.78; 0.47)

0.05

  1. Outcomes presented as means with 95% confidence intervals at baseline and after 24 weeks of supplement for both groups
  2. CI Confidence Interval, P P for difference between the two groups of supplement, HRV Heart rate variability, PWV Pulse wave velocity, BP blood pressure, AIx central Augmentation Index